Cytespace Africa Laboratories has launched in-region genomic sequencing capabilities, enabling faster clinical trial insights and strengthening Africa’s role in global health research and innovation.
Cytespace Africa Laboratories has announced the launch of its in-region Next-Generation Sequencing (NGS) capabilities, marking a significant step forward in Africa’s clinical research landscape.
The development allows sponsors to generate critical genomic insights directly within Africa, removing the delays and logistical challenges often associated with offshore testing.
As clinical trials become increasingly complex, access to timely and high-quality genomic data has become essential — particularly in infectious disease research. Historically, many sponsors operating in Africa have faced a difficult trade-off between accessing advanced genomic insights and maintaining the speed required for effective trials.
By bringing NGS capabilities in-region, Cytespace is addressing this challenge head-on.
“For too long, sponsors have had to choose between accessing advanced genomic insights and maintaining speed in their trials, especially in regions like Africa,” said Scott Houlton, CEO of MLM Medical Labs.
“By bringing NGS capabilities in-region through Cytespace Africa Laboratories, we’re removing that trade-off, giving our clients faster, more actionable data where it matters most.”
The new platform is fully integrated within the laboratory’s molecular diagnostics and Biosafety Level 3 (BSL-3) infrastructure, enabling advanced analysis of both pathogens and host responses. This supports deeper insights into drug resistance, pathogen evolution, vaccine response and safety signals.
A key application is targeted NGS for tuberculosis drug development. The technology enables rapid identification of resistance mutations, improved characterisation of multidrug-resistant and extensively drug-resistant TB, and more accurate analysis of transmission patterns.
For sponsors, this translates into shorter turnaround times, improved decision-making and stronger support for adaptive trial design.
Cytespace Africa Laboratories builds on more than two decades of experience, having supported over 1,300 global clinical trials across a range of therapeutic areas. The addition of NGS marks a shift from a traditional central laboratory role toward a broader position as a genomic intelligence partner.
With established infrastructure, in-region expertise and alignment with global standards, the laboratory is positioning itself as a key enabler of clinical development across Africa.
As demand for faster, more precise data continues to grow, in-region genomic capabilities are expected to play an increasingly important role in strengthening research, improving outcomes and advancing healthcare innovation across the continent.
